SCHEMBL30794874

SCHEMBL30794874

CCOC(=O)Nc1ccc(NCc2ccc(Cl)s2)cc1C(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 1/20 0.46
KCNQ3 O43525 4/20 0.46
KCNQ2 O43526 4/20 0.46
KCNQ4 P56696 3/20 0.46
KCNQ5 Q9NR82 3/20 0.46
FFAR1 O14842 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 4/20 0.39
MAPT P10636 3/20 0.39
DHODH Q02127 2/20 0.39
LMNA P02545 2/20 0.39
TP53 P04637 2/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2072355 1.00 UTS2R (0.46) UTS2RKCNQ3KCNQ2KCNQ4KCNQ5
SCHEMBL2071657 0.88 KCNQ2 (0.46) UTS2RKCNQ3KCNQ2KCNQ4KCNQ5
SCHEMBL30795429 0.86 KCNQ3 (0.47) KCNQ3KCNQ2KCNQ4KCNQ5FFAR1
SCHEMBL2069986 0.86 KCNQ3 (0.47) KCNQ3KCNQ2KCNQ4KCNQ5FFAR1
SCHEMBL2070740 0.86 SMN1; SMN2 (0.53) KCNQ3KCNQ2KCNQ4KCNQ5FFAR1
SCHEMBL30795181 0.84 KCNQ2 (0.62) KCNQ3KCNQ2KCNQ4KCNQ5FFAR1
SCHEMBL3101974 0.84 KCNQ2 (0.62) KCNQ3KCNQ2KCNQ4KCNQ5FFAR1
SCHEMBL2070853 0.84 KCNQ3 (0.46) UTS2RKCNQ3KCNQ2KCNQ4KCNQ5
SCHEMBL30796658 0.82 KCNQ3 (0.44) KCNQ3KCNQ2KCNQ4KCNQ5FFAR1
SCHEMBL2071189 0.82 KCNQ3 (0.44) KCNQ3KCNQ2KCNQ4KCNQ5FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed